Skip to main content
OpenTrials
Completed

NCT Number: NCT05027191

Effect of Desflurane Versus Sevoflurane With Recent Bio-markers on Renal and Hepatic Functions

Studying the effects of both inhalational anesthetics desflurane and sevoflurane on hepatic integrity and renal function, guided by recent blood and urine biomarkers in patients undergoing laparoscopic cholecystectomy surgery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postoperative Complications Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

25 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Theodor Bilharz Research Institute

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • American Society of Anesthesiologists (ASA) Class: I&II.
  • Elective laparoscopic cholecystectomy.
  • Age: 25-55 years.
  • Gender: Both male and female.
  • Body Mass Index (BMI): 18.5-24.9 km2-(Normal weight).

Exclusion criteria

  • Extremes of age.
  • Abnormal hepatic function by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values outside the normal range.
  • Abnormal renal function by blood urea nitrogen (BUN) and creatinine above the normal ranges.
  • Hypertension, unstable angina pectoris or myocardial infarction within the last six months.
  • Pregnancy and lactation.
  • Bronchial asthma.
  • Drug allergies.
  • Alcohol or drug addiction.
  • General anesthesia within the last three months.

Treatment and study plan

Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Diagnostic Test

The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.

Desflurane

Drug

Desflurane

Sevoflurane

Drug

Sevoflurane

Primary outcomes

  1. Change in serum Neutrophil gelatinase-associated lipocalin (NGAL)

    Time frame: a change from baseline NGAL serum level at 6 hours

    Renal Biomarker

Secondary outcomes

  1. Change in serum Arginase

    Time frame: Baseline, first hour, six hours, after 24 hours

    Hepatic biomarker

  2. Change in serum Cystatin-c

    Time frame: Baseline, first hour, six hours, after 24 hours

    Hepatic biomarker

  3. Change in urine Netrin-1

    Time frame: Baseline, first hour, six hours, after 24 hours

    Renal biomarker

  4. Change in urine Kidney Injury Molecule

    Time frame: Baseline, first hour, six hours, after 24 hours

    Renal biomarker

  5. Change in urine Interleukin-18

    Time frame: Baseline, first hour, six hours, after 24 hours

    cytokines

  6. Change in urine Alpha-Glutathione S-Transferase

    Time frame: Baseline, first hour, six hours, after 24 hours

    Liver biomarker

Sponsors and collaborators

Lead sponsor

Theodor Bilharz Research Institute

Other

Collaborators

  • Cairo University

Registry information

Official study title

Evaluating the Effect of Desflurane Versus Sevoflurane With Recent Biomarkers of Renal and Hepatic Function in Laparoscopic Cholecystectomy Patients: A Prospective Randomized Double Blinded Study

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Aug 30, 2021
Registry last updated
Aug 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.